36,661 Charles River Laboratories International, Inc. $CRL Shares Purchased by TD Waterhouse Canada Inc.

Key Points

• TD Waterhouse Canada Inc. increased its Charles River Laboratories stake by 81,468.9% in the third quarter, purchasing 36,661 additional shares and bringing its holdings to 36,706 shares valued at approximately $10.8 million.
• Charles River reported quarterly revenue of about $1 billion and adjusted earnings of $3.02 per share, beating analyst estimates, although revenue declined 2.7% year over year. Institutional investors collectively own 98.91% of the company.
• Analysts maintain a generally positive view, with the stock carrying a “Moderate Buy” consensus rating and an average price target of $302.33. However, company insiders sold 91,971 shares worth approximately $26 million during the latest quarter.

TD Waterhouse Canada Inc. increased its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 81,468.9% in the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 36,706 shares of the medical research company's stock after purchasing an additional 36,661 shares during the quarter. TD Waterhouse Canada Inc. owned 0.08% of Charles River Laboratories International worth $10,829,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently bought and sold shares of CRL. Continuum Advisory LLC acquired a new position in Charles River Laboratories International during the second quarter valued at approximately $30,000. Activest Wealth Management grew its stake in Charles River Laboratories International by 25.9% during the third quarter. Activest Wealth Management now owns 277 shares of the medical research company's stock worth $82,000 after buying an additional 57 shares during the period. SHP Wealth Management purchased a new stake in Charles River Laboratories International during the fourth quarter worth approximately $85,000. Hilltop National Bank increased its position in shares of Charles River Laboratories International by 28.7% in the second quarter. Hilltop National Bank now owns 569 shares of the medical research company's stock worth $129,000 after acquiring an additional 127 shares in the last quarter. Finally, Trust Asset Management LLC acquired a new stake in shares of Charles River Laboratories International in the second quarter worth $129,000. Hedge funds and other institutional investors own 98.91% of the company's stock.

Charles River Laboratories International Stock Performance

Charles River Laboratories International stock opened at $300.35 on Monday. The firm has a market capitalization of $14.34 billion, a PE ratio of -61.93, a price-to-earnings-growth ratio of 2.80 and a beta of 1.40. Charles River Laboratories International, Inc. has a one year low of $146.20 and a one year high of $333.30. The stock's 50 day moving average price is $289.50 and its 200 day moving average price is $228.15. The company has a debt-to-equity ratio of 0.92, a quick ratio of 1.04 and a current ratio of 1.35.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last released its quarterly earnings results on Wednesday, August 5th. The medical research company reported $3.02 earnings per share for the quarter, topping analysts' consensus estimates of $2.77 by $0.25. Charles River Laboratories International had a positive return on equity of 15.75% and a negative net margin of 5.96%. The firm had revenue of $1 billion during the quarter, compared to analysts' expectations of $980.53 million. During the same quarter in the prior year, the business earned $3.12 EPS. Charles River Laboratories International's quarterly revenue was down 2.7% compared to the same quarter last year. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS. As a group, sell-side analysts expect that Charles River Laboratories International, Inc. will post 11.38 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on the stock. Royal Bank Of Canada raised their target price on shares of Charles River Laboratories International from $282.00 to $322.00 and gave the company an "outperform" rating in a research note on Friday, September 25th. Barclays upped their price target on shares of Charles River Laboratories International from $300.00 to $330.00 and gave the stock an "overweight" rating in a research report on Friday, September 25th. UBS Group initiated coverage on shares of Charles River Laboratories International in a research report on Wednesday, September 30th. They set a "buy" rating and a $357.00 price target for the company. Robert W. Baird increased their price target on Charles River Laboratories International from $291.00 to $334.00 and gave the company an "outperform" rating in a report on Friday, September 25th. Finally, Mizuho raised their price objective on Charles River Laboratories International from $264.00 to $295.00 and gave the company a "neutral" rating in a research report on Friday, September 25th. Two research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $302.33.

Insider Buying and Selling at Charles River Laboratories International

In related news, Director James Foster sold 33,561 shares of the firm's stock in a transaction on Tuesday, August 25th. The shares were sold at an average price of $300.00, for a total transaction of $10,068,300.00. Following the completion of the sale, the director directly owned 31,596 shares of the company's stock, valued at approximately $9,478,800. This trade represents a 51.51% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Birgit Girshick sold 6,500 shares of the firm's stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $279.90, for a total transaction of $1,819,350.00. Following the sale, the chief executive officer directly owned 36,013 shares of the company's stock, valued at approximately $10,080,038.70. The trade was a 15.29% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 91,971 shares of company stock valued at $26,033,968. 1.30% of the stock is owned by company insiders.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc is a contract research and laboratory services company that supports pharmaceutical, biotechnology, medical device and academic research organizations. The company provides products and services used throughout the drug-development process, from early discovery and research through preclinical testing and manufacturing support.

Its offerings include research models, laboratory animal management, discovery and safety assessment services, toxicology testing, bioanalysis, and support for biologic, cell and gene therapy programs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.